


The Fund's objective is to achieve long term capital and income growth.
| Name | % Net Assets |
|---|---|
| AstraZeneca PLC | 1.9% |
| Royal Dutch Shell PLC (CL B) | 1.8% |
| GlaxoSmithKline PLC | 1.8% |
| Centrica PLC | 1.6% |
| Daily Mail & General Trust PLC | 1.5% |
| RSA Insurance Group PLC | 1.5% |
| British American Tobacco PLC | 1.5% |
| VT Group PLC | 1.5% |
| Babcock International Group PLC | 1.4% |
| Smith & Nephew PLC | 1.3% |
| Key | % Net Assets |
|---|---|
| 1.9% | |
| 1.8% | |
| 1.8% | |
| 1.6% | |
| 92.9% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 170.00p |
| Currency | GBP |
| Change | 0.50p |
| % | 0.29% |
| YTD change | 17.20p |
| YTD % | 11.26% |
| Fund Inception | 31/12/2002 |
|---|---|
| Fund Manager | Tim Russell |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | £500 |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.10 |
You are here: research